Titles and Roles
- Associate Professor, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Director, Genitourinary Medical Oncology Program
- Winship Cancer Institute of Emory University
- Research Program
- Discovery and Developmental Therapeutics
Mehmet Asim Bilen, MD, is associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A board certified medical oncologist, Dr. Bilen is actively involved in clinical research and patient care in the area of genitourinary cancers. He serves as director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Winship Clinical and Translational Review Committee.
Dr. Bilen is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
Dr. Bilen received his MD from Hacettepe University Faculty of Medicine in Ankara, Turkey. He completed a postdoctoral fellowship in Molecular Pathology and a clinical fellowship in Hematology/Oncology at UT MD Anderson Cancer Center in Houston, Texas. His postgraduate medical education also included residency training at Baylor College of Medicine in Houston, Texas.
As a postdoctoral fellow at UT MD Anderson Cancer Center, Dr. Bilen worked with Dr. Sue-Hwa Lin on developing biomarkers and therapeutic strategies that can be applied in clinical settings to promote early detection and to improve treatment options for prostate cancer bone metastasis. He focused on the role of cadherin-11 in prostate cancer bone metastasis and generating monoclonal antibodies that inhibited that metastasis. He showed that inhibition of cell adhesion by a cadherin-11 antibody thwarts prostate cancer bone metastasis and monotherapy using a cadherin-11 antibody is a suitable option for prevention.
Dr. Bilen continued to focus on genitourinary malignancies after becoming a clinical fellow at UT MD Anderson Cancer Center where he worked on several projects in clinical and translational research. In 2015, he was selected to participate in the AACR/ASCO Vail workshop.
Below is a listing of current federal grants for the above principal investigator.
Dr. Bilen has published a number of peer-reviewed original papers and reviews in leading journals including Cancer Research, Molecular Cancer Research, FASEB J, Journal of Pathology, Cancer and Clinical and Experimental Metastasis and has authored or co-authored several abstracts for presentations at professional meetings.
Publications Publication Date
Dr. Bilen's recent awards include:
- UT MD Anderson Cancer Center GU Medical Oncology Distinguished Alumni Award, 2023
- Young Investigator Award, Prostate Cancer Foundation, 2019
- Winship Invest$ Prostate Cancer Research Pilot Award, 2019
- Mentorship of Graduate Students Award, Winship Cancer Institute, 2018
- Top Clinical Trials Enroller - All Sites and Top Clinical Trials Enroller - NCTN Trials, Winship Cancer Institute, 2018
- Emory Woodruff Health Sciences Synergy Award, 2018
- Winship Invest$ Pilot Grant Award, 2018
- Winship Invest$ Prostate Cancer Research Pilot Award, 2017
- Top clinical trial enrollment (Clifton campus), Winship Cancer Institute, July-December 2017
- Waun Ki Hong Award for Clinical Investigation, UT MD Anderson Cancer Center, 2016
- ASCO/AACR Methods in Clinical Cancer Research Workshop, 2015